/CVKD
CVKD Stock - Cadrenal Therapeutics, Inc. Common Stock
Healthcare|BiotechnologyNASDAQ
$7.11-3.53%
$0.26 (-3.53%) • Dec 19
61
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.4
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.76
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+350.1%upside
Target: $32.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CVKD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$7.04 – $7.18
TARGET (TP)$32.00
STOP LOSS$6.54
RISK/REWARD1:43.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.10
52W High$22.90
52W Low$6.76
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | $-1,266 |
| Gross Margin | N/A | N/A | N/A |
| Operating Income | $-10,960,619 | $-7,632,843 | $-2,701,630 |
| Net Income | $-10,651,368 | $-8,357,086 | $-6,714,329 |
| Net Margin | N/A | N/A | N/A |
| EPS | $-8.73 | $-9.63 | $-8.66 |
Company Overview
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$4
Average Target
↓ 43.7% Downside
Now
$4
Low
$4
Average
$4
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 18th 2023 | Noble Capital Markets | Initiation | Outperform | $4 |
Earnings History & Surprises
CVKDBeat Rate
33%
Last 9 quarters
Avg Surprise
-2.0%
EPS vs Estimate
Beats / Misses
3/5
1 met exactly
Latest EPS
$-1.31
Q4 2025
EPS Surprise History
Q1 24
+44.4%
$-0.75vs$-1.35
Q2 24
-42.9%
$-1.50vs$-1.05
Q3 24
+88.2%
$-2.25vs$-19.04
Q4 24
-19.1%
$-2.18vs$-1.83
Q1 25
-60.2%
$-2.74vs$-1.71
Q2 25
-27.4%
$-2.09vs$-1.64
Q3 25
-16.9%
$-1.87vs$-1.60
Q4 25
+15.5%
$-1.31vs$-1.55
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 12, 2026 | $-1.21 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-1.55 | $-1.31 | +15.5% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $-1.60 | $-1.87 | -16.9% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-1.64 | $-2.09 | -27.4% | ✗ MISS |
Q1 2025 | Mar 13, 2025 | $-1.71 | $-2.74 | -60.2% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-1.83 | $-2.18 | -19.1% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-19.04 | $-2.25 | +88.2% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-1.05 | $-1.50 | -42.9% | ✗ MISS |
Q1 2024 | Mar 11, 2024 | $-1.35 | $-0.75 | +44.4% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-1.05 | $-1.05 | 0.0% | = MET |
Q3 2023 | Aug 10, 2023 | — | $-1.35 | — | — |
Q2 2023 | May 10, 2023 | — | $-0.41 | — | — |
Q1 2023 | Mar 30, 2023 | — | $-6.46 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.09 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.04 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.02 | — | — |
Latest News
Cadrenal Therapeutics Acquires VLX-1005 And Related 12-Lipoxygenase Assets From Veralox Therapeutics; Terms Not Disclosed
📈 PositiveBenzinga•Dec 11, 2025, 01:09 PM
Cadrenal Therapeutics Q3 EPS $(1.31) Beats $(1.53) Estimate
📈 PositiveBenzinga•Nov 10, 2025, 02:04 PM
Cadrenal Acquires Assets Of eXIthera Pharma In $15M Milestone-Linked Deal, Adds Royalty Pathway For Future Global Sales
📈 PositiveBenzinga•Sep 15, 2025, 12:04 PM
Frequently Asked Questions about CVKD
What is CVKD's current stock price?
Cadrenal Therapeutics, Inc. Common Stock (CVKD) is currently trading at $7.11 per share. The stock has moved -3.53% today.
What is the analyst price target for CVKD?
The average analyst price target for CVKD is $32.00, based on 1 analyst.
What sector is Cadrenal Therapeutics, Inc. Common Stock in?
Cadrenal Therapeutics, Inc. Common Stock operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CVKD's market cap?
Cadrenal Therapeutics, Inc. Common Stock has a market capitalization of $0.01 billion, making it a small-cap company.
Does CVKD pay dividends?
No, Cadrenal Therapeutics, Inc. Common Stock does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCLGN
CollPlant Biotechnologies Ltd.
$1.52
Mkt Cap: $0.0B
IBIO
iBio, Inc.
$1.98
Mkt Cap: $0.0B
ITRM
Iterum Therapeutics plc
$0.37
Mkt Cap: $0.0B
KLTO
Klotho Neurosciences, Inc.
$0.39
Mkt Cap: $0.0B
NRSN
NeuroSense Therapeutics Ltd.
$0.81
Mkt Cap: $0.0B
NRXS
NeurAxis, Inc.
$3.22
Mkt Cap: $0.0B
RLYB
Rallybio Corporation
$0.79
Mkt Cap: $0.0B
SONN
Sonnet BioTherapeutics Holdings, Inc.
$1.26
Mkt Cap: $0.0B
TAOX
TAO Synergies Inc.
$5.03
Mkt Cap: $0.0B
XCUR
Exicure, Inc.
$5.92
Mkt Cap: $0.0B
Explore stocks similar to CVKD for comparison